Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units

Rhea-AI Filing Summary

Cherry Brian N reported acquisition or exercise transactions in this Form 4 filing.

Atara Biotherapeutics director Brian N. Cherry received a grant of 24,000 shares of common stock on June 11, 2026 as a compensation award. The shares are in the form of restricted stock units that vest in three equal annual installments on the first, second, and third anniversaries of June 11, 2026, subject to his continuous service. Following this grant, Cherry directly holds 62,320 shares of Atara common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cherry Brian N

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Common Stock — 62,320 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 24,000 shares Grant price: $0.00 per share Post-transaction holdings: 62,320 shares +1 more

4 metrics

RSU grant size 24,000 shares Restricted stock units granted June 11, 2026

Grant price $0.00 per share Reported award price for RSU grant

Post-transaction holdings 62,320 shares Total common shares held directly after grant

Vesting schedule 1/3 each year over 3 years Vests on first, second, third anniversaries of June 11, 2026

Key Terms

restricted stock units, Grant, award, or other acquisition, continuous service

3 terms

restricted stock units financial

"These restricted stock units shall vest as to 1/3 of the shares..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

continuous service financial

"subject to the Reporting Person's continuous service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cherry Brian N

(Last) (First) (Middle)

C/O ATARA BIOTHERAPEUTICS, INC.

1280 RANCHO CONEJO BOULEVARD

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atara Biotherapeutics, Inc. [ ATRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		24,000(1)	A	$0	62,320	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units shall vest as to 1/3 of the shares on the first, second and third anniversaries of June 11, 2026, subject to the Reporting Person's continuous service.

	/s/ John Chao, Attorney-in-Fact for Brian Cherry	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Atara Biotherapeutics (ATRA) disclose for Brian N. Cherry?

Atara Biotherapeutics reported that director Brian N. Cherry received a grant of 24,000 restricted stock units on June 11, 2026. This is a compensation-related award rather than an open-market stock purchase or sale.

How many Atara Biotherapeutics (ATRA) shares does Brian N. Cherry hold after this Form 4?

After the June 11, 2026 grant, Brian N. Cherry directly holds 62,320 shares of Atara Biotherapeutics common stock. This total includes the newly awarded 24,000 restricted stock units reported in the Form 4 filing.

What are the vesting terms of Brian N. Cherry’s 24,000 Atara (ATRA) restricted stock units?

The 24,000 restricted stock units vest in three equal installments. One-third of the grant vests on each of the first, second, and third anniversaries of June 11, 2026, if Brian N. Cherry maintains continuous service.

Was the Atara Biotherapeutics (ATRA) Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant of 24,000 restricted stock units to director Brian N. Cherry. It is a compensation-related acquisition at a reported price of $0.00 per share, not an open-market buy or sell transaction.

What transaction code was used in Atara Biotherapeutics (ATRA) director Brian N. Cherry’s Form 4?

The transaction was reported with code “A,” indicating a grant, award, or other acquisition. This reflects restricted stock units granted to Brian N. Cherry as part of his compensation, rather than a market trade.